Skip to content
DataLookout
Menu

NCT07774325

A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later, enrollment reduced 38%.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reduced: 16 → 10 participants
    • Primary completion pushed from Oct 6, 2026 to Feb 21, 2027
    • Study completion pushed from Oct 26, 2026 to Mar 8, 2027
  2. Notable Eligibility criteria expanded, about 9 words
    • Enrollment closed, study ongoing
    • Site details revised
  3. Notable Recruitment opened
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Timeframe: up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
Timeframe: up to 4 days

Secondary (1)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Arms and interventions

Treatment sequence 1Experimental

Sequence: 1. \- Reference treatment (BI 3000202) 2. \- Test treatment 1 (BI 3000202 + Ciclosporin) 3. \- Test treatment 2 (BI 3000202 + Itraconazole)

Treatment sequence 2Experimental

Sequence: 1. \- Test treatment 1 (BI 3000202 + Ciclosporin) 2. \- Reference treatment (BI 3000202) 3. \- Test treatment 2 (BI 3000202 + Itraconazole)

Drugs: BI 3000202, Ciclosporin, Itraconazole

Sites

1 site in 1 country

  • Humanpharmakologisches Zentrum BiberachBiberach, Germany